Circuit Court Sides With PTAB on Invalidating J&J’s Remicade Patent

A federal circuit court upheld a PTO Patent Trial and Appeal Board ruling that a Johnson & Johnson patent for Remicade, which earned the company nearly $7 billion in 2016, is invalid.
Source: Drug Industry Daily